MULTISPECIFIC ANTIBODY-DRUG CONJUGATES
Patent Information
- Application Number
- ARP20250101126
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-30
- Filing Date
- 2025-04-28
- Publication Date
- 2026-10-28
Claims
This disclosure relates to the field of antibody-drug conjugates (ADCs). In particular, it relates to the field of therapeutic antibodies for the treatment of diseases, especially cancer. More specifically, it relates to multispecific antibody-drug conjugates.
1. An antibody-drug conjugate comprising an antibody with a first and a second heavy chain, wherein each heavy chain comprises a CH3 domain, wherein the CH3 domain of the first heavy chain comprises at least one substitution of a neutral amino acid residue for a positively charged amino acid residue, and the CH3 domain of the second heavy chain comprises at least one substitution of a neutral amino acid residue for a negatively charged amino acid residue.
18. An antibody-drug conjugate that competes with an antibody-drug conjugate according to any of claims 1-17 for binding to EGFR and / or c-MET.
19. A pharmaceutical composition comprising an effective amount of an antibody-drug conjugate according to any of claims 1-18, and a pharmaceutically acceptable carrier.
20. An antibody-drug conjugate according to any of claims 1-18, or a pharmaceutical composition according to claim 19, for use in therapy.
24. A method for producing an antibody-drug conjugate, wherein the method comprises: – providing an antibody comprising a first and a second heavy chain, wherein each heavy chain comprises a CH3 domain, wherein the CH3 domain of the first heavy chain comprises at least one substitution of a neutral amino acid residue for a positively charged amino acid residue, and the CH3 domain of the second heavy chain comprises at least one substitution of a neutral amino acid residue for a negatively charged amino acid residue; and – coupling a linker-drug combination to the antibody.